Results 31 to 40 of about 6,728 (169)

Circulating Endocannabinoids in Canine Multicentric Lymphoma Patients

open access: yesFrontiers in Veterinary Science, 2022
The endocannabinoid system is increasingly being implicated in the pathogenesis and progression of various human cancers. Specifically, increased levels of 2-arachidonoylglycerol (2-AG) and oleoythanolamide (OEA) have been demonstrated in human diffuse ...
Jennifer K. Hay   +4 more
doaj   +1 more source

Chemical tools to modulate 2‐arachidonoylglycerol biosynthesis

open access: yesBiotechnology and Applied Biochemistry, 2017
Abstract2‐Arachidonoylglycerol (2‐AG) is an important endogenous signaling lipid that activates the cannabinoid receptors (CB1R and CB2R), thereby regulating a diverse range of physiological processes including anxiety, appetite, inflammation, memory, pain sensation, and nociception.
Deng, H., Stelt, M. van der
openaire   +4 more sources

Endocannabinoid metabolism inhibition has no effect on spontaneous fear recovery or extinction resistance in Lister hooded rats

open access: yesFrontiers in Pharmacology, 2022
Endocannabinoid transmission is emerging as a target for treating anxiety-related disorders, given its regulation of fear extinction. Boosting anandamide levels via inhibition of its metabolism by fatty acid amide hydrolase (FAAH) can enhance extinction,
William G. Warren   +5 more
doaj   +1 more source

2-Arachidonoylglycerol (2-AG) membrane transport: History and outlook [PDF]

open access: yesThe AAPS Journal, 2006
Only a few studies have addressed the transport of 2-arachidonoylglycerol (2-AG), a naturally occurring agonist for cannabinoid receptors. Based upon saturation kinetics, these early reports have proposed that 2-AG enters the cell by a specific 2-AG transporter, via the putative anandamide transporter, or by simple diffusion. In this review, the uptake
Anita, Hermann   +2 more
openaire   +2 more sources

Targeting Monoacylglycerol Lipase in Pursuit of Therapies for Neurological and Neurodegenerative Diseases

open access: yesMolecules, 2021
Neurological and neurodegenerative diseases are debilitating conditions, and frequently lack an effective treatment. Monoacylglycerol lipase (MAGL) is a key enzyme involved in the metabolism of 2-AG (2-arachidonoylglycerol), a neuroprotective ...
Anca Zanfirescu   +4 more
doaj   +1 more source

2-Arachidonoylglycerol Signaling in Forebrain Regulates Systemic Energy Metabolism [PDF]

open access: yesCell Metabolism, 2012
The endocannabinoid system plays a critical role in the control of energy homeostasis, but the identity and localization of the endocannabinoid signal involved remain unknown. In the present study, we developed transgenic mice that overexpress in forebrain neurons the presynaptic hydrolase, monoacylglycerol lipase (MGL), which deactivates the ...
Jung, Kwang-Mook   +12 more
openaire   +6 more sources

Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects

open access: yesNutrition & Metabolism, 2011
We have previously shown that krill oil (KO), more efficiently than fish oil, was able to downregulate the endocannabinoid system in different tissues of obese zucker rats.
Giordano Elena   +10 more
doaj   +1 more source

A natural substrate-based fluorescence assay for inhibitor screening on diacylglycerol lipase α

open access: yesJournal of Lipid Research, 2015
The endocannabinoid 2-arachidonoylglycerol (2-AG) is predominantly biosynthesized by sn-1-diacylglycerol lipase α (DAGL-α) in the CNS. Selective inhibitors of DAGL-α will provide valuable insights in the role of 2-AG in endocannabinoid signaling ...
Tom van der Wel   +6 more
doaj   +1 more source

Anandamide Metabolites Protect against Seizures through the TRP Channel Water Witch in Drosophila melanogaster

open access: yesCell Reports, 2020
Summary: Endocannabinoids protect against seizures, but their mechanism of action is still unclear, as they can have effects independent of known cannabinoid receptors. Using Drosophila melanogaster, which lacks canonical cannabinoid receptors, we report
Jack A. Jacobs, Amita Sehgal
doaj   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy